Shattuck Labs, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Shattuck Labs, Inc. (STTK) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 18.07 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- Shattuck Labs, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 61.14M shares, a 580.39% increase year-over-year.
- Shattuck Labs, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 8.99M shares, a 19.67% increase year-over-year.
- Shattuck Labs, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 7.51M shares, a 26.98% increase year-over-year.
- Shattuck Labs, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 5.91M shares, a 56.69% increase year-over-year.
- Shattuck Labs, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 61.64M shares, a 734.00% increase from fiscal 2024.
- Shattuck Labs, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 7.39M shares, a 33.58% increase from fiscal 2023.
- Shattuck Labs, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 5.53M shares, a 22.44% increase from fiscal 2022.
- Shattuck Labs, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 4.52M shares, a 84.54% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 18.07M shares 10-Q · filed 2026-08-11 | ||||
| 2026-03-31 | 61.14M shares 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | 61.64M shares 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | 61.60M shares 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | 8.83M shares 10-Q · filed 2026-08-11 | ||||
| 2025-03-31 | 8.99M shares 10-Q · filed 2026-05-07 | ||||
| 2024-12-31 | 7.39M shares 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | 7.43M shares 10-Q · filed 2025-11-06 | ||||
| 2024-06-30 | 7.48M shares 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | 7.51M shares 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | 5.53M shares 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | 6.01M shares 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | 6.05M shares 10-Q · filed 2024-08-01 | ||||
| 2023-03-31 | 5.91M shares 10-Q · filed 2024-05-02 | ||||
| 2022-12-31 | 4.52M shares 10-K · filed 2024-02-29 | ||||
| 2022-09-30 | 4.37M shares 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | 4.21M shares 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | 3.77M shares 10-Q · filed 2023-05-09 | ||||
| 2021-12-31 | 2.45M shares 10-K · filed 2023-02-23 | ||||
| 2021-09-30 | 2.49M shares 10-Q · filed 2021-11-09 | 2.49M shares 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | 2.58M shares 10-Q · filed 2022-08-11 | ||||
| 2021-03-31 | 2.73M shares 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | 2.75M shares 10-K · filed 2022-03-15 | 2.75B shares 10-K · filed 2021-03-16 | |||
| 2020-09-30 | 22.86M shares 10-Q · filed 2021-11-09 | 22.86M shares 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | 22.03M shares 10-Q · filed 2021-08-12 | ||||
| 2020-03-31 | 12.99M shares 10-Q · filed 2021-05-10 | ||||
| 2019-12-31 | 9.13B shares 10-K · filed 2021-03-16 | ||||
| 2019-09-30 | 8.78M shares 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |